Alyftrek 10-50-125 MG tablet 14S
Ended Awarded Last action
- Contract number
- SPE2DR26FCRM6
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,995
Award facts
- Contract value 100% obligated
- $20,995.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $20,995.46 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for 14-count tablets of Alyftrek 10-50-125 mg. The award, issued on December 5, 2025, with an ultimate completion date of December 8, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (SPE2DR) established under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to provide pharmaceutical and medical supply support to Department of Defense healthcare operations worldwide.
DMS Pharmaceutical Group has maintained a substantial federal contracting presence since its registration in the System for Award Management in July 2001, serving as a critical supplier within the federal pharmaceutical supply chain. The company's product portfolio spans branded and generic prescription medications, biologics, vaccines, specialty pharmaceuticals, and medical consumables, with previous delivery orders ranging from under $100 to over $115,000. The PPV-G GEN V contract, awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036, positions DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting recurring medical supply needs across military healthcare facilities globally.
Quick answers
Who was awarded contract SPE2DR26FCRM6?
SPE2DR26FCRM6 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 5, 2025.
How much is contract SPE2DR26FCRM6 worth?
The government has obligated $20,995 on SPE2DR26FCRM6.
Is contract SPE2DR26FCRM6 an order under another contract?
Yes. SPE2DR26FCRM6 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRM6 competed?
The extent of competition for SPE2DR26FCRM6 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award